Sandoz commits to increasing patient access to important respiratory treatments

November 19, 2014 – Today, on World Chronic Obstructive Pulmonary Disease (COPD) Day, Sandoz reaffirms its commitment to providing needed treatments for respiratory conditions such as COPD. COPD is a progressive disease that makes it hard to breathe, with symptoms that can affect aspects of everyday life1,2.

The most common symptoms of COPD include shortness of breath, abnormal sputum production, a chronic cough, wheezing and chest tightness4. Daily activities, such as walking up a short flight of stairs, can become very difficult as the condition …

/by

Global health challenges – including life expectancy – are influenced by gender

November 19, 2014 – The health challenges facing both men and women globally are heavily influenced by gender. Today, International Men’s Day, the global health community seeks to promote positive male role models, celebrate men’s positive contributions to society, focus on men’s health and wellbeing, highlight discrimination against males, and improve gender relations and promote gender equality.

Globally, men die younger than women. There are a number of reasons for this, such as biological, societal and behavioral differences.

Gender differences in health …

/by

Sandoz supports prudent use of antibiotics on EU Antibiotic Awareness Day

November 18, 2014 – European Antibiotic Awareness Day is an annual European public health initiative to raise awareness about the threat to public health of antibiotic resistance and the importance of prudent antibiotic use.

The latest data confirms that across the European Union the number of patients infected by resistant bacteria is increasing and that antibiotic resistance is a major threat to public health.

Prudent use of antibiotics can help stop resistant bacteria from developing and help keep antibiotics effective for the use of future generations.

…

/by

Sandoz sponsors diabetes awareness training for healthcare professionals in Ethiopia

November 14, 2014 – Today is World Diabetes Day. Globally, 382 million people were living with diabetes in 2013. In 2035, it is estimated that 592 million people will be living with diabetes, a 55% increase from today1.

In sub-Saharan Africa, non-communicable diseases like diabetes are on the rise2. However, many African countries are ill-prepared to deal with these new healthcare challenges2.

In Ethiopia, Sandoz has initiated a new project called Sandoz Executive Medical Management Academy (SEMMA), an educational program for …

/by

Sandoz recognizes World Pneumonia Day, raising awareness of the leading cause of infectious death globally among children under five

Pneumonia kills 1 million children each year. Amoxicillin is the #1 treatment for childhood pneumonia. Sandoz holds the leading position in antibiotics and amoxicillin is one of our top ten products worldwide.

world-pneumonia-day

In June 2014, Sandoz committed to the world’s …

/by

Sandoz launches ready-to-use oral formulation of ACC® cough medicine in Ukraine

  • Sandoz launches new ready to use oral formulation of ACC® in the Ukrainian market
  • ACC® oral solution is used for children from 2 years old
  • New form has cherry flavor and is available with convenient dispenser

Kiev, November 12, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC® cough medicine.

ACC® oral solution (active substance acetylcysteine) is used to treat acute and chronic bronchopulmonary diseases when it is necessary to reduce …

/by

Sandoz launches first generic version of cyclophosphamide injection, USP

Princeton, New Jersey, November 10, 2014 – Sandoz today announced the US market introduction of cyclophosphamide injection, USP.

Sandoz is launching cyclophosphamide injection, USP, through collaboration with Jiangsu Hengrui Medicine Co., the owner of the product’s Abbreviated New Drug Application (ANDA).

Cyclophosphamide for injection, USP, is a chemotherapy agent used to treat certain types of cancer in adults and pediatric patients. It is also used in selected cases of biopsy proven “minimal change” nephrotic syndrome in children. New cases of leukemia, …

/by

Sandoz receives approvals in Baltics for innovative respiratory inhaler AirFluSal® Forspiro®

  • Regulatory authorities in Estonia, Latvia and Lithuania grant marketing authorizations for AirFluSal® Forspiro®
  • Approval for 50-250 and 50-500µg dosage forms
  • AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, November 4, 2014 – Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). …

/by

RAND projects $44.2 billion reduction in U.S. spend on biologics over the next decade from introduction of biosimilars

November 03, 2014 – Today the RAND Corporation projected that the introduction of biosimilar drugs in the US will reduce direct spending on biologics by USD 44.2 billion from 2014 to 2024. Currently there are no biosimilars approved by the FDA for use in the US. Products submitted for review by FDA through the Biologics Price Competition and Innovation Act pathway are developed with highly similar quality, safety and efficacy to marketed biologics, but they come at a lower price. A biosimilar will be approved if …

/by

Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter

Basel, October 28, 2014 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company.”

  • Net sales up 4% (+5% cc)1 in Q3, with operating margin increase across Q3 and 9M
    • Net sales of USD 14.7 billion grew 4% (+5% cc2) in Q3
    • Strong …
/by